Ralph Tiedt

8.0k total citations · 1 hit paper
34 papers, 4.5k citations indexed

About

Ralph Tiedt is a scholar working on Molecular Biology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ralph Tiedt has authored 34 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 16 papers in Hematology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ralph Tiedt's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Platelet Disorders and Treatments (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Ralph Tiedt is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Platelet Disorders and Treatments (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Ralph Tiedt collaborates with scholars based in Switzerland, United States and Spain. Ralph Tiedt's co-authors include Radek C. Skoda, Róbert Královics, Andreas Buser, André Tichelli, Francesco Passamonti, Mario Cazzola, Jakob Passweg, Hui Hao-Shen, Tibor Schomber and Jürg Schwaller and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

Ralph Tiedt

32 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders

2005 2.6k citations Róbert Královics, Francesco Passamonti et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Ralph Tiedt

Since Specialization

Citations

This map shows the geographic impact of Ralph Tiedt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralph Tiedt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralph Tiedt more than expected).

Fields of papers citing papers by Ralph Tiedt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralph Tiedt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralph Tiedt. The network helps show where Ralph Tiedt may publish in the future.

Co-authorship network of co-authors of Ralph Tiedt

This figure shows the co-authorship network connecting the top 25 collaborators of Ralph Tiedt. A scholar is included among the top collaborators of Ralph Tiedt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralph Tiedt. Ralph Tiedt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	511LBA (PB-511) LBA Posters: Selective Targeting of Cyclin E1 Using Molecular Glue Degraders in CCNE1 Amplified Solid Malignancies 2024 ·European Journal of Cancer ·(unknown), (unknown), Yun Liu, (unknown), Chao Quan, Xiomara Lucas, (unknown), (unknown), Christopher King, (unknown), (unknown), (unknown), (unknown), Janneke C. Alers, Benjamin Demarco, Markus Warmuth, Simon Townson, Bernhard Fasching, (unknown), Ralph Tiedt	0
2	Abstract 3294: The GSPT1 molecular glue degrader MRT-2359 is active against prostate cancer 2024 ·Cancer Research ·Ralph Tiedt, (unknown), (unknown), Débora Bonenfant, Rajiv Narayan, Owen B. Wallace, Markus Warmuth	4
3	Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer 2024 ·Lung Cancer ·Enriqueta Felip, Giulio Metro, Daniel Shao-Weng Tan, Juergen Wolf, Michael Mark, Michael Boyer, Brett Hughes, Alessandra Bearz, Denis Moro‐Sibilot, Xiuning Le, Javier Puente, Bartomeu Massutí, Ralph Tiedt, (unknown), (unknown), (unknown), Manuel Cobo	5
4	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment 2020 ·Investigational New Drugs ·Jean‐Pierre Delord, Guillem Argilés, Jérôme Fayette, Lori J. Wirth, Stefan Kasper, Salvatore Siena, Ricard Mesı́a, Rossana Berardi, Andrés Cervantes, Jeroen Dekervel, Sylvia Zhao, (unknown), Huai-Xiang Hao, Ralph Tiedt, (unknown), Andrea P. Myers, Lillian L. Siu	17
5	Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation 2019 ·Clinical Cancer Research ·Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang, Huai-Xiang Hao, Angela Tam, Hui Qin Wang, Jinsheng Liang, Matthew T. DiMare, Hyo-Eun Carrie Bhang, Youzhen Wang, Pascal Furet, William R. Sellers, Francesco Hofmann, Joseph Schoepfer, Ralph Tiedt	105
6	New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse 2019 ·ACS Medicinal Chemistry Letters ·Frédéric Stauffer, Andreas Weiss, Clemens Scheufler, Henrik Möbitz, (unknown), Kim S. Beyer, (unknown), Daniel Guthy, Michael Kiffe, Bernard Van Eerdenbrugh, Ralph Tiedt, Christoph Gaul	27
7	A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma 2019 ·Journal of Neuro-Oncology ·Martin J. van den Bent, Analía Azaro, Filip De Vos, Juan Manuel Sepúlveda-Sánchez, W.K. Alfred Yung, Patrick Y. Wen, Andrew B. Lassman, Markus Joerger, Ghazaleh Tabatabai, Jordi Rodón, Ralph Tiedt, Sylvia Zhao, (unknown), Yi Cheng, (unknown), O. Alejandro Balbin, Hefei Zhang, Wolfgang Wick	36
8	The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models 2018 ·Oncotarget ·Sunkyu Kim, Ralph Tiedt, Alice Loo, Thomas Horn, Scott Delach, (unknown), Kristy Haas, Barbara Schacher Engstler, (unknown), Maria Pinzon-Ortiz, Iain J. Mulford, Michael Acker, Rajiv Chopra, Christopher T. Brain, Emmanuelle di Tomaso, William R. Sellers, Giordano Caponigro	58
9	Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach 2017 ·ACS Medicinal Chemistry Letters ·Henrik Möbitz, Rainer Machauer, Philipp Holzer, Andrea Vaupel, Frédéric Stauffer, (unknown), Giorgio Caravatti, Clemens Scheufler, César Fernández Fernández, Ulrich Hommel, Ralph Tiedt, Kim S. Beyer, Chao Chen, Hugh Zhu, Christoph Gaul	42
10	ACTR-74. A PHASE IB/II, OPEN-LABEL, MULTICENTER STUDY OF CAPMATINIB (INC280) ALONE AND IN COMBINATION WITH BUPARLISIB (BKM120) IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA 2017 ·Neuro-Oncology ·Martin J. van den Bent, Analía Azaro, Filip De Vos, Juan Manuel Sepúlveda-Sánchez, W.K. Alfred Yung, Patrick Y. Wen, Andrew B. Lassman, Markus Joerger, Ghazaleh Tabatabai, Jordi Rodón, Ralph Tiedt, Sylvia Zhao, (unknown), (unknown), Andrea P. Myers, Wolfgang Wick	1
11	Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach 2016 ·ACS Medicinal Chemistry Letters ·Chao Chen, Hugh Zhu, Frédéric Stauffer, Giorgio Caravatti, (unknown), Rainer Machauer, Philipp Holzer, Henrik Möbitz, Clemens Scheufler, Martin Klumpp, Ralph Tiedt, Kim S. Beyer, (unknown), Daniel Guthy, Michael Kiffe, Jeff Zhang, Christoph Gaul	51
12	Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia 2016 ·Leukemia ·(unknown), Vanessa J. Craig, (unknown), Julius Gräsel, Barbara Schacher Engstler, Greg Hoffman, Florian Nigsch, Swann Gaulis, Louise Barys, Moriko Ito, Júlia Aguadé-Gorgorió, Beat Bornhäuser, Jean‐Pierre Bourquin, (unknown), (unknown), Masato Murakami, William R. Sellers, F. Hofmann, Juerg Schwaller, Ralph Tiedt	84
13	A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients 2011 ·Cancer Research ·Ralph Tiedt, (unknown), Pascal Furet, B.A. Appleton, (unknown), Joseph Schoepfer, Emily Buck, David A. Ruddy, John E. Monahan, Michael D. Jones, Jutta Blank, Dorothea Haasen, Peter Drueckes, Markus Wartmann, Clive McCarthy, William R. Sellers, Francesco Hofmann	99
14	Abstract 4738: Cellular resistance screening with a novel selective c-Met inhibitor reveals a spectrum of missense mutations that partially overlap with activating mutations found in cancer patients 2011 ·Cancer Research ·Ralph Tiedt, (unknown), Pascal Furet, B.A. Appleton, Joseph Schoepfer, David A. Ruddy, John E. Monahan, Michael D. Jones, Jutta Blank, Dorothea Haasen, Peter Drueckes, Markus Wartmann, Clive McCarthy, Francesco Hofmann	4
15	Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes 2008 ·Blood ·Ralph Tiedt, Jörn Coers, Sandra Ziegler, Adrian Wiestner, Hui Hao-Shen, Caroline Bornmann, Johannes Schenkel, Svetlana Karakhanova, Frédéric J. de Sauvage, Carl W. Jackson, Radek C. Skoda	44
16	A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family 2008 ·Haematologica ·Kai Liu, Róbert Královics, Zbigniew Rudzki, B. Grabowska, Andreas Buser, Damla Olcaydu, (unknown), Ralph Tiedt, Peter Frank, Krzysztof Okoń, A. P. C. van der Maas, Radek C. Skoda	32
17	Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo 2006 ·Blood ·Ralph Tiedt, Tibor Schomber, Hui Hao-Shen, Radek C. Skoda	311
18	A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders breakdown → 2005 ·New England Journal of Medicine ·Róbert Královics, Francesco Passamonti, Andreas Buser, (unknown), Ralph Tiedt, Jakob Passweg, André Tichelli, Mario Cazzola, Radek C. Skoda	2571
19	Zim17, a Novel Zinc Finger Protein Essential for Protein Import into Mitochondria 2004 ·Journal of Biological Chemistry ·Lena Burri, (unknown), S Fredersdorf, Ralph Tiedt, Michael N. Hall, Trevor Lithgow	46
20	The RING finger protein Siah-1 regulates the level of the transcriptional coactivator OBF-1 2001 ·The EMBO Journal ·Ralph Tiedt	65

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact